Urigen Pharmaceuticals, Inc. And Oceana Therapeutics Collaborate on FDA Meeting Preparation
SAN FRANCISCO--(BUSINESS WIRE)--Urigen Pharmaceuticals, Inc. (OTCBB:URGP), a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that the Company and Oceana Therapeutics have agreed to jointly prepare for a meeting with the U.S. Food & Drug Administration regarding the continued development of URG101.